



AHAM World Series - Biotechnology Fund

A feeder fund that seeks to achieve capital appreciation over medium to long term period through investments in biotechnology and biotechnology-related companies worldwide.

Fund Category

Feeder (Wholesale)

Fund Type

Growth

Target Fund Manager

Janus Henderson Investors Europe S.A.

Target Fund

Janus Henderson Horizon Fund – Biotechnology Fund

Benchmark

N/A

Base Currency

USD

Launch Date / IOP

May 30, 2024 / USD0.50_(USD)
May 30, 2024 / MYR0.50_(MYR)
May 30, 2024 / MYR0.50_(MYR Hedged)

Financial Year End

October 31

Subscription

Cash

Initial Sales Charge

Max 5.50% of the NAV per Unit

Annual Management Fee

Max 1.80% per annum

Minimum Investment /
Minimum Subsequent Investment

USD10,000 / USD5,000_(USD)
MYR30,000 / MYR10,000_(MYR Hedged)
MYR30,000 / MYR10,000_(MYR)

As at May 30, 2025*



Fund Size / NAV Per Unit

USD0.7million / USD0.4471_(USD)
MYR7.9million / MYR0.4037_(MYR)
MYR11.9million / MYR0.4356_(MYR Hedged)

Performance Record as at May 30 2025*
Not applicable as the Fund has less than one year track record

May, 2024 to May, 2025 NAV-NAV prices and assuming reinvestment of distributions into the Fund, gross investment based in USD. The value of Units may go down as well as up. Past performance is not indicative of future performance.
Source: MorningStar

Target Fund Top Holdings as at April 30 2025#	
Equities	%
Vertex Pharmaceuticals	8.8
Amgen	5.1
Ascendis Pharma	4.6
Soleno Therapeutics	4.5
Argenx	4.2
Verona Pharma	4.0
Avidity Biosciences	3.9
Madrigal Pharmaceuticals	3.4
Revolution Medicines	3.3
Akero Therapeutics	3.1



Performance Table as at May 30 2025*					
Total Return (%)	1 Month	1 Year	3 Year	Inception	Since
Not applicable as the Fund has less than one year track record					
Annualised Return (%)	1 Year	3 Year	5 Year	Inception	Since
Not applicable as the Fund has less than one year track record					
Calendar Year Return (%)	Year To Date	2024	2023	2022	
Not applicable as the Fund has less than one year track record					

Asset Allocation as at May 30 2025*	
Janus Henderson Horizon Fund – Biotechnology Fund Class A2 (USD)	97.7%
Cash & Cash Equivalents	2.3%

Income Distribution History
Distribution Policy: The fund will distribute income subject to the availability of income. Incidentally: USD, MYR Hedged, MYR

* The data provided above is that of the Fund and is a percentage of NAV as at May 30 2025. All figures are subject to frequent changes on a daily basis and the percentages might not add up to 100% due to rounding.

The data provided above is that of the Fund by Janus Henderson Investors Europe S.A. and is a percentage of NAV of the Target Fund as at April 30 2025 as the data is provided by Target Fund Manager after AHAM Capital publication cut-off date. Please note that asset exposure for the Target Fund is subject to frequent changes on daily basis and the percentages might not add up to 100% due to rounding.

To invest in a Class other than MYR Class and/or MYR-Hedged Class, investors are required to have a foreign currency account with any Financial Institution as all transactions relating to the particular foreign currency will ONLY be made via telegraphic transfer.

Where a distribution is declared, investors are advised that following the issue of additional Units/distribution, the NAV per Unit will be reduced from cum-distribution NAV to ex-distribution NAV.

A copy of the Information Memorandum and Product Highlights Sheet ("PHS") can be obtained at AHAM Asset Management's ("AHAM Capital") sales offices or at www.aham.com.my. Investors are advised to read and understand the contents of Information Memorandum and the corresponding PHS before investing. There are fees and charges involved when investing in the Fund. Investors are advised to consider and compare the fees and charges as well of the risks carefully before investing. Investors should make their own assessment of the risks involved in investing and should seek professional advice, where necessary. The price of units and distribution payable, if any, may go down as well as up and past performance of the fund should not be taken as indicative of its future performance. The Securities Commission Malaysia has not reviewed this marketing/promotional material and takes no responsibility for the contents of this marketing/promotional material and expressly disclaims all liability, however arising from this marketing/promotional material.

Built On Trust

JUNE 2025 | FUNDamentals